Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Parkinson's Disease

  Free Subscription


Articles published in Neurosci Lett

Retrieve available abstracts of 136 articles:
HTML format



Single Articles


    February 2024
  1. TAKIZAWA S, Ohuchi K, Fujimaki A, Ito T, et al
    Effects of alpha7 nicotinic acetylcholine receptor agonist against alpha-synuclein-induced neurotoxicity.
    Neurosci Lett. 2024;823:137654.
    PubMed     Abstract available


  2. CAKIR M, Sacmaci H
    The relationship of salusins with Parkinson's Disease, Alzheimer's Disease, and acute ischemic stroke: A preliminary study.
    Neurosci Lett. 2024 Feb 11:137683. doi: 10.1016/j.neulet.2024.137683.
    PubMed     Abstract available


    January 2024
  3. LIU H, Gong Z, Li Z, Ye T, et al
    Distribution, connection and function of ALDH1A1(+)/TH(+) neurons in substantia nigra pars reticulata of mouse.
    Neurosci Lett. 2024;818:137555.
    PubMed     Abstract available


    December 2023
  4. HU Q, Xu L, Liu X, Wang Y, et al
    Adenosine A(2A) receptor antagonist KW6002 protects against A53T mutant alpha-synuclein-induced brain damage and neuronal apoptosis in Parkinson's disease mice by restoring autophagic flux.
    Neurosci Lett. 2023 Dec 27:137610. doi: 10.1016/j.neulet.2023.137610.
    PubMed     Abstract available


  5. HUANG W, Wang Y, Huang W
    Mangiferin alleviates 6-OHDA-induced Parkinson's disease by inhibiting AKR1C3 to activate Wnt signaling pathway.
    Neurosci Lett. 2023 Dec 22:137608. doi: 10.1016/j.neulet.2023.137608.
    PubMed     Abstract available


  6. RAJAN S, Sood A, Jain R, Kamatham PT, et al
    Fingolimod exerts neuroprotection by regulating S1PR1 mediated BNIP3-PINK1-Parkin dependent mitophagy in rotenone induced mouse model of Parkinson's disease.
    Neurosci Lett. 2023;820:137596.
    PubMed     Abstract available


    November 2023
  7. BILISTER EGILMEZ C, Azak Pazarlar B, Alper Erdogan M, Erbas O, et al
    Neuroprotective effect of dexpanthenol on rotenone-induced Parkinson's disease model in rats.
    Neurosci Lett. 2023 Nov 29:137575. doi: 10.1016/j.neulet.2023.137575.
    PubMed     Abstract available


  8. GUO F, Kang J, Xu J, Wei S, et al
    Genome-wide identification of m(6)A-associated single nucleotide polymorphisms in complex diseases of nervous system.
    Neurosci Lett. 2023;817:137513.
    PubMed     Abstract available


  9. SINGH A, Panhelainen A, Voutilainen MH
    Feasibility of combining alpha-synuclein aggregation and 6-OHDA in embryonic midbrain culture for modeling dopamine neuron degeneration.
    Neurosci Lett. 2023;816:137510.
    PubMed     Abstract available


  10. PAN Y, Zong Q, Li G, Wu Z, et al
    Nuclear localization of alpha-synuclein induces anxiety-like behavior in mice by decreasing hippocampal neurogenesis and pathologically affecting amygdala circuits.
    Neurosci Lett. 2023;816:137490.
    PubMed     Abstract available


    October 2023
  11. MONAGHAN AS, Hooyman A, Dibble LE, Mehta SH, et al
    Cognitive Predictors of Responsiveness to Reactive Step Training in People with Parkinson's Disease at Fall-Risk.
    Neurosci Lett. 2023;817:137517.
    PubMed     Abstract available


    September 2023
  12. STATZ M, Schleuter F, Weber H, Kober M, et al
    Subthalamic nucleus deep brain stimulation does not alter growth factor expression in a rat model of stable dopaminergic deficiency.
    Neurosci Lett. 2023;814:137459.
    PubMed     Abstract available


  13. GENG X, Zou Y, Li J, Li S, et al
    Mesenchymal stem cell exosomes rich in miR-23b-3p affect the Wnt signaling pathway and promote neuronal autophagy to alleviate PD symptoms.
    Neurosci Lett. 2023;814:137437.
    PubMed     Abstract available


    August 2023
  14. HEO EJ, Lee Y, Hyung Seo M, Yeo S, et al
    Association between SGK1 and alpha-synuclein in skeletal muscle in an MPTP-induced Parkinson's disease model.
    Neurosci Lett. 2023 Aug 25:137464. doi: 10.1016/j.neulet.2023.137464.
    PubMed     Abstract available


  15. KAPLAN ALGIN A, Tomruk C, Gozde Aslan C, Saban Akkurt S, et al
    Effects of ozone treatment to the levels of neurodegeneration biomarkers after rotenone induced rat model of Parkinson's disease.
    Neurosci Lett. 2023;814:137448.
    PubMed     Abstract available


  16. HE P, Gao Y, Shi L, Li Y, et al
    Motor progression phenotypes in early-stage Parkinson's Disease: A clinical prediction model and the role of glymphatic system imaging biomarkers.
    Neurosci Lett. 2023 Aug 8:137435. doi: 10.1016/j.neulet.2023.137435.
    PubMed     Abstract available


  17. TAN Z, Lin Y, Zhou M, Guo W, et al
    Correlation of SV2C rs1423099 single nucleotide polymorphism with sporadic Parkinson's disease in Han population in Southern China.
    Neurosci Lett. 2023 Aug 4:137426. doi: 10.1016/j.neulet.2023.137426.
    PubMed     Abstract available


    July 2023
  18. TIAN Q, Sun X, Li C, Yang Y, et al
    CD33 polymorphisms and Parkinson's disease Parkinson's disease in northern Chinese Han population: A case-control study.
    Neurosci Lett. 2023;812:137400.
    PubMed     Abstract available


  19. LI Y, Li F, Liu X, Zu J, et al
    Association between serum neurofilament light chain levels and sleep disorders in patients with Parkinson's disease.
    Neurosci Lett. 2023 Jul 10:137394. doi: 10.1016/j.neulet.2023.137394.
    PubMed     Abstract available


  20. JIN H, Shen H, Liu C, Wang L, et al
    Decreased Serum BDNF Contributes to the Onset of REM Sleep Behavior Disorder in Parkinson's Disease Patients.
    Neurosci Lett. 2023 Jul 7:137380. doi: 10.1016/j.neulet.2023.137380.
    PubMed     Abstract available


    June 2023
  21. HWAN SHIN J, Ah Shin D, Young Lee C, Jin Chang H, et al
    Inability to suppress head rotation during the saccade test as a clinical biomarker for cognitive dysfunction in Parkinson's disease.
    Neurosci Lett. 2023 Jun 22:137356. doi: 10.1016/j.neulet.2023.137356.
    PubMed     Abstract available


  22. ZHENG Q, Ma P, Yang P, Zhai S, et al
    Alpha lipoic acid ameliorates motor deficits by inhibiting ferroptosis in Parkinson's disease.
    Neurosci Lett. 2023 Jun 10:137346. doi: 10.1016/j.neulet.2023.137346.
    PubMed     Abstract available


    May 2023
  23. WANG X, Wei W, Bai Y, Shen Y, et al
    Intrinsic Brain Activity Alterations in Patients With Parkinson's disease.
    Neurosci Lett. 2023 May 15:137298. doi: 10.1016/j.neulet.2023.137298.
    PubMed     Abstract available


    April 2023
  24. ZHANG X, Zhong X, Wang L, Li H, et al
    Effects of soluble TREM2 on motor progression in Parkinson's disease.
    Neurosci Lett. 2023 Apr 25:137277. doi: 10.1016/j.neulet.2023.137277.
    PubMed     Abstract available


  25. ZHANG X, Li L, Qi L, Fu Y, et al
    Distribution pattern of iron deposition in the basal ganglia of different motor subtypes of Parkinson's disease.
    Neurosci Lett. 2023 Apr 13:137249. doi: 10.1016/j.neulet.2023.137249.
    PubMed     Abstract available


  26. SHIDA TKF, de Oliveira CEN, da Silva Fragoso de Campos D, Los Angeles E, et al
    Effect of freezing of gait and dopaminergic medication in the biomechanics of lower limbs in the gait of patients with Parkinson's disease compared to neurologically healthy.
    Neurosci Lett. 2023;806:137250.
    PubMed     Abstract available


  27. MURAKAMI Y, Nishijima H, Nakamura T, Furukawa T, et al
    Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
    Neurosci Lett. 2023;806:137248.
    PubMed     Abstract available


  28. DONG L, Chang Q, Ma J, Liu C, et al
    Associations of blood UCH-L1 and NfL levels with cognitive dysfunction in Parkinson's disease patients.
    Neurosci Lett. 2023;804:137219.
    PubMed     Abstract available


  29. MA C, Wei X, Wang F, Zhang T, et al
    Tumor necrosis factor alpha-induced protein 3 mediates inflammation and neuronal autophagy in Parkinson's disease via the NFkappaB and mTOR pathways.
    Neurosci Lett. 2023 Apr 3:137223. doi: 10.1016/j.neulet.2023.137223.
    PubMed     Abstract available


  30. MORRISON S, Reilly N, Schussler E, Kerr G, et al
    The effect of standing posture on amplitude and variability of postural tremor in Parkinson's disease.
    Neurosci Lett. 2023 Apr 3:137220. doi: 10.1016/j.neulet.2023.137220.
    PubMed     Abstract available


  31. YUAN M, Du N, Song Z
    Primary motor area-related injury of anterior central gyrus in Parkinson's disease with dyskinesia: a study based on MRS and Q-Space.
    Neurosci Lett. 2023 Apr 3:137224. doi: 10.1016/j.neulet.2023.137224.
    PubMed     Abstract available


    March 2023
  32. GOMEZ-MARTIN A, Fuentes JM, Jordan J, Galindo MF, et al
    Detection of rare Genetic Variations in the promoter regions of the ATG16L gene in Parkinson's patients.
    Neurosci Lett. 2023 Mar 21:137195. doi: 10.1016/j.neulet.2023.137195.
    PubMed     Abstract available


  33. LI W, Pan X, Li M, Ling L, et al
    Impact of age on the rotenone-induced sporadic Parkinson's disease model using Drosophila melanogaster.
    Neurosci Lett. 2023 Mar 13:137187. doi: 10.1016/j.neulet.2023.137187.
    PubMed     Abstract available


    February 2023
  34. OMAR AHMAD S, Longhurst J, Stiles D, Downard L, et al
    A meta-analysis of exercise intervention and the effect on Parkinson's Disease Symptoms.
    Neurosci Lett. 2023 Feb 28:137162. doi: 10.1016/j.neulet.2023.137162.
    PubMed     Abstract available


  35. YAN JH, Ge YL, Wang PZ, Li W, et al
    Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.
    Neurosci Lett. 2023 Feb 20:137140. doi: 10.1016/j.neulet.2023.137140.
    PubMed     Abstract available


  36. LI Z, Li Y, Xu X, Gu J, et al
    Exosomes rich in Wnt5 improved circadian rhythm dysfunction via enhanced PPARgamma activity in the 6-hydroxydopamine model of Parkinson's disease.
    Neurosci Lett. 2023 Feb 20:137139. doi: 10.1016/j.neulet.2023.137139.
    PubMed     Abstract available


  37. WITZIG V, Alosaimi F, Temel Y, Schulz JB, et al
    Gait improvement by high-frequency stimulation of the subthalamic nucleus in Parkinsonian mice is not associated with changes of the cholinergic system in the pedunculopontine nucleus.
    Neurosci Lett. 2023 Feb 16:137134. doi: 10.1016/j.neulet.2023.137134.
    PubMed     Abstract available


  38. CARNEY AE, Clarke C, Pratt WE
    Administration of neuropeptide Y into the rat nucleus accumbens shell, but not core, attenuates the motivational impairment from systemic dopamine receptor antagonism by alpha-flupenthixol.
    Neurosci Lett. 2023;797:137069.
    PubMed     Abstract available


    January 2023
  39. SUN X, Tian Q, Yang Z, Li Y, et al
    Association of AQP4 single nucleotide polymorphisms (rs335929 and rs2075575) with Parkinson's disease: a case-control study.
    Neurosci Lett. 2023 Jan 7:137062. doi: 10.1016/j.neulet.2023.137062.
    PubMed     Abstract available


  40. PAL P, Roy S, Chowdhury A, Chatterjee R, et al
    Parkinson's Disease-associated 18 bp Promoter Variant of DJ-1 Alters REST Binding and Regulates its Expression.
    Neurosci Lett. 2023 Jan 2:137051. doi: 10.1016/j.neulet.2023.137051.
    PubMed     Abstract available


    December 2022
  41. DE SIQUEIRA EA, Magalhaes EP, de Menezes RRPPB, Sampaio TL, et al
    Vitamin D3 actions on astrocyte cells: A target for therapeutic strategy in Parkinson's disease?
    Neurosci Lett. 2022;793:136997.
    PubMed     Abstract available


    November 2022
  42. PAN S, Wang L, Wang Y, Dong X, et al
    Transplantation of ERK gene-modified bone marrow mesenchymal stem cells ameliorates cognitive deficits in a 6-hydroxydopamine rat model of Parkinson's disease.
    Neurosci Lett. 2022 Nov 30:136993. doi: 10.1016/j.neulet.2022.136993.
    PubMed     Abstract available


  43. CHEN Y, Li Y, Li C, Zhu D, et al
    Dexmedetomidine alleviates pain in MPTP-treated mice by activating the AMPK/mTOR/NF-kappaB pathways in astrocytes.
    Neurosci Lett. 2022;791:136933.
    PubMed     Abstract available


  44. HU ZX, Pu JL, Zheng R, Yan YQ, et al
    Mitochondrial morphology and synaptic structure altered in the retina of parkin-deficient mice.
    Neurosci Lett. 2022;790:136888.
    PubMed     Abstract available


    October 2022
  45. ZHANG X, Wang S, Li X, Li X, et al
    Hemoglobin-binding alpha-synuclein levels in erythrocytes are elevated in patients with multiple system atrophy.
    Neurosci Lett. 2022;789:136868.
    PubMed     Abstract available


  46. YU Z, Huang L, Xia Y, Cheng S, et al
    Analysis of the m6A modification regulators in the substantia nigra and striatum of MPTP-induced Parkinson's disease mice.
    Neurosci Lett. 2022 Oct 6:136907. doi: 10.1016/j.neulet.2022.136907.
    PubMed     Abstract available


    September 2022
  47. LIU X, Qi Y, Zhao G, Zhang Z, et al
    Expression profiles of microRNAs in midbrain of MPTP-treated mice determined by microRNA sequencing.
    Neurosci Lett. 2022;788:136841.
    PubMed     Abstract available


  48. SADEGHIAN Z, Eyvari Brooshghalan S, Sabahi M, Nourouzi N, et al
    Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease.
    Neurosci Lett. 2022 Sep 23:136884. doi: 10.1016/j.neulet.2022.136884.
    PubMed     Abstract available


  49. LIU Q, Jiang B, Zou M, Wan HJ, et al
    A genetic analysis of Chinese patients with early-onset Parkinson' s disease.
    Neurosci Lett. 2022 Sep 20:136880. doi: 10.1016/j.neulet.2022.136880.
    PubMed     Abstract available


    August 2022
  50. BERG A, Bech S, Aasly J, Farrer MJ, et al
    Autonomic dysfunction in Parkinson's disease: Results from the Faroese Parkinson's disease cohort.
    Neurosci Lett. 2022;785:136789.
    PubMed     Abstract available


  51. ZHENG JH, Sun WH, Ma JJ, Wang ZD, et al
    Structural and functional abnormalities in Parkinson's disease based on voxel-based morphometry and resting-state functional magnetic resonance imaging.
    Neurosci Lett. 2022;788:136835.
    PubMed     Abstract available


    July 2022
  52. CHATTERJEE K, Choudhury S, Banerjee R, Siddique U, et al
    Is peripheral alpha synuclein a marker for gait velocity in Parkinson's disease?
    Neurosci Lett. 2022;786:136819.
    PubMed     Abstract available


  53. XU X, Li Z, Zuo H, Chen H, et al
    Mesenchymal stem cell-derived exosomes altered neuron cholesterol metabolism via Wnt5a-LRP1 axis and alleviated cognitive impairment in a progressive Parkinson's disease model.
    Neurosci Lett. 2022 Jul 20:136810. doi: 10.1016/j.neulet.2022.136810.
    PubMed     Abstract available


  54. EL AISSOUQ A, Bouachrine M, Ouammou A, Khalil F, et al
    Homology modeling, virtual screening, molecular docking, molecular dynamic (MD) simulation, and ADMET approaches for identification of natural anti-Parkinson agents targeting MAO-B protein.
    Neurosci Lett. 2022 Jul 13:136803. doi: 10.1016/j.neulet.2022.136803.
    PubMed     Abstract available


    June 2022
  55. ROY A, Banerjee R, Choudhury S, Chatterjee K, et al
    Novel Inflammasome and Oxidative Modulators in Parkinson's Disease: A Prospective Study.
    Neurosci Lett. 2022 Jun 30:136768. doi: 10.1016/j.neulet.2022.136768.
    PubMed     Abstract available


  56. RAN C, Brodin L, Gellhaar S, Westerlund M, et al
    Glucocerebrosidase variant T369M is not a risk factor for Parkinson's disease in Sweden.
    Neurosci Lett. 2022;784:136767.
    PubMed     Abstract available


  57. XU B, Wang X, Xu Z, Li Q, et al
    N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson's disease.
    Neurosci Lett. 2022 Jun 20:136751. doi: 10.1016/j.neulet.2022.136751.
    PubMed     Abstract available


  58. LI C, Hou B, Li X, Yang Z, et al
    Role of CD36 rs1761667 AA genotype in the expression of inflammatory cytokines and Parkinson's disease progression: A case-control study in a northern Han Chinese population.
    Neurosci Lett. 2022;784:136736.
    PubMed     Abstract available


  59. SHI X, Zheng J, Ma J, Wang Z, et al
    Insulin-like growth factor in Parkinson's disease is related to nonmotor symptoms and the volume of specific brain areas.
    Neurosci Lett. 2022;783:136735.
    PubMed     Abstract available


  60. YANG Z, Xue L, Li C, Li M, et al
    Association between ABCA7 gene polymorphisms and Parkinson's disease susceptibility in a northern Chinese Han population.
    Neurosci Lett. 2022;784:136734.
    PubMed     Abstract available


    May 2022
  61. WANG LX, Liu C, Shao YQ, Jin H, et al
    Peripheral Blood Inflammatory Cytokines are Associated with Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease.
    Neurosci Lett. 2022 May 20:136692. doi: 10.1016/j.neulet.2022.136692.
    PubMed     Abstract available


  62. SHKODINA AD, Tarianyk KA, Boiko DI, Zehravi M, et al
    Cognitive and affective disturbances in patients with Parkinson's disease: perspectives for classifying of motor/neuropsychiatric subtypes.
    Neurosci Lett. 2022 May 6:136675. doi: 10.1016/j.neulet.2022.136675.
    PubMed     Abstract available


    April 2022
  63. ZHANG J, Wang M, Zhao Y, Zhang Y, et al
    Alpha-lipoic acid improved motor function in MPTP-induced Parkinsonian mice by reducing neuroinflammation in the nigral and spinal cord.
    Neurosci Lett. 2022;781:136669.
    PubMed     Abstract available


  64. LIM HS, Park G
    Resilin, an insect-derived elastomeric protein, protects dopaminergic neurons in Parkinson disease models.
    Neurosci Lett. 2022;781:136667.
    PubMed     Abstract available


  65. CHEN W, Hou C, Wang Y, Hong L, et al
    Circular RNA circTLK1 regulates dopaminergic neuron injury during Parkinson's disease by targeting miR-26a-5pDAPK1.
    Neurosci Lett. 2022 Apr 18:136638. doi: 10.1016/j.neulet.2022.136638.
    PubMed     Abstract available


    March 2022
  66. WANG Y, Luan M, Xue L, Jin J, et al
    Evaluation of the relationship between SORL1 gene polymorphism and Parkinson's disease in the Chinese population.
    Neurosci Lett. 2022;778:136602.
    PubMed     Abstract available


  67. NING P, Li K, Ren H, Yang H, et al
    Rare missense variants in the PPP2R5D gene associated with Parkinson's disease in the Han Chinese population.
    Neurosci Lett. 2022;776:136564.
    PubMed     Abstract available


    February 2022
  68. LUAN M, Jin J, Wang Y, Li X, et al
    Association of PGLYRP2 gene polymorphism and sporadic Parkinson's disease in northern Chinese Han population.
    Neurosci Lett. 2022;775:136547.
    PubMed     Abstract available


  69. COSTA TM, Simieli L, Bersotti FM, Mochizuki L, et al
    Gait and posture are correlated domains in Parkinson's disease.
    Neurosci Lett. 2022 Feb 19:136537. doi: 10.1016/j.neulet.2022.136537.
    PubMed     Abstract available


  70. NICHOLATOS JW, Tran D, Liu Y, Hirst WD, et al
    Lysophosphatidylcholine acyltransferase 1 promotes pathology and toxicity in two distinct cell-based alpha-synuclein models.
    Neurosci Lett. 2022;772:136491.
    PubMed     Abstract available


  71. WANG XL, Feng ST, Chen B, Hu D, et al
    Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
    Neurosci Lett. 2022;774:136515.
    PubMed     Abstract available


    January 2022
  72. VIREL A, Johansson J, Axelsson J, Ericsson M, et al
    N-acetylcysteine decreases dopamine transporter availability in the non-lesioned striatum of the 6-OHDA hemiparkinsonian rat.
    Neurosci Lett. 2022;770:136420.
    PubMed     Abstract available


  73. ZHAO Y, Qi Y, Li Q, Quan H, et al
    Connexin43 inhibition attenuated dopaminergic neuronal loss in the lipopolysaccharide-induced mice model of Parkinson's disease.
    Neurosci Lett. 2022;771:136471.
    PubMed     Abstract available


  74. VITORINO LC, Oliveira KF, da Silva WAB, de Andrade Gomes CAB, et al
    Physical exercise influences astrocytes in the striatum of a Parkinson's disease male mouse model.
    Neurosci Lett. 2022;771:136466.
    PubMed     Abstract available


  75. AFSHARI D, Shakeri J, Khodamoradi M, Nejad Shahrokh Abadi R, et al
    Efficacy of electroconvulsive therapy in Parkinson's disease: a clinical trial.
    Neurosci Lett. 2022 Jan 10:136449. doi: 10.1016/j.neulet.2022.136449.
    PubMed     Abstract available


    December 2021
  76. OSTRAKHOVITCH EA, Song ES, Macedo JKA, Gentry MS, et al
    Analysis of circulating metabolites to differentiate Parkinson's disease and essential tremor.
    Neurosci Lett. 2021;769:136428.
    PubMed     Abstract available


  77. SANG T, He J, Wang J, Zhang C, et al
    Alterations in white matter fiber in Parkinson's disease across different cognitive stages.
    Neurosci Lett. 2021 Dec 24:136424. doi: 10.1016/j.neulet.2021.136424.
    PubMed    


  78. LI Y, Li Z, Gu J, Xu X, et al
    Exosomes isolated during dopaminergic neuron differentiation suppressed neuronal inflammation in a rodent model of Parkinson's disease.
    Neurosci Lett. 2021;771:136414.
    PubMed     Abstract available


  79. PARK DG, Kang J, An YS, Chang J, et al
    Association of plasma alpha-synuclein with cardiac (123)I-MIBG scintigraphy in early Parkinson's disease.
    Neurosci Lett. 2021;770:136399.
    PubMed     Abstract available


    November 2021
  80. LI B, Yang S, Ye J, Chu S, et al
    Flavin-containing monooxygenase 1 deficiency promotes neuroinflammation in dopaminergic neurons in mice.
    Neurosci Lett. 2021;764:136222.
    PubMed     Abstract available


    October 2021
  81. PENGV B, Gong Z, Zhang Y, Shen B, et al
    Self-paced learning and privileged information Based KRR classification algorithm for diagnosis of Parkinson's disease.
    Neurosci Lett. 2021 Oct 29:136312. doi: 10.1016/j.neulet.2021.136312.
    PubMed     Abstract available


  82. BIAN K, Liu C, Wang Y, Xue Y, et al
    Orexin-B exerts excitatory effects on nigral dopaminergic neurons and alleviates motor disorders in MPTP parkinsonian mice.
    Neurosci Lett. 2021;765:136291.
    PubMed     Abstract available


  83. PANDI S, Chinniah R, Sevak V, Ravi PM, et al
    Association of HLA-DRB1, DQA1 and DQB1 alleles and haplotype in Parkinson's disease from South India.
    Neurosci Lett. 2021;765:136296.
    PubMed     Abstract available


    September 2021
  84. IKUNO M, Yamakado H, Amano I, Hatanaka Y, et al
    Mitochondrial Dysfunction in a Mouse Model of Prodromal Parkinson's Disease: A Metabolomic Analysis.
    Neurosci Lett. 2021 Sep 24:136267. doi: 10.1016/j.neulet.2021.136267.
    PubMed     Abstract available


  85. JIN JUNG Y, Choi H, Oh E
    Effects of particulate matter and nicotine for the MPP+-induced SH-SY5Y cells: Implication for Parkinson's disease.
    Neurosci Lett. 2021 Sep 23:136265. doi: 10.1016/j.neulet.2021.136265.
    PubMed    


  86. POTTENGER AE, Bartlett MJ, Sherman SJ, Falk T, et al
    Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment.
    Neurosci Lett. 2021 Sep 15:136251. doi: 10.1016/j.neulet.2021.136251.
    PubMed     Abstract available


  87. PAULETTI C, Mannarelli D, Locuratolo N, Maffucci A, et al
    Serotonergic central tone in Parkinson's disease with fatigue: evidence from the loudness dependence of auditory evoked potentials (LDAEP).
    Neurosci Lett. 2021 Sep 9:136242. doi: 10.1016/j.neulet.2021.136242.
    PubMed     Abstract available


  88. CHUNG J, Ushakova A, Doitsidou M, Tzoulis C, et al
    The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: a longitudinal observational study.
    Neurosci Lett. 2021 Sep 9:136243. doi: 10.1016/j.neulet.2021.136243.
    PubMed     Abstract available


    August 2021
  89. MURATA T, Tochio N, Utsunomiya-Tate N
    Physicochemical characterization of the G51D mutation of alpha-synuclein that is responsible for its severe cytotoxicity.
    Neurosci Lett. 2021;760:136077.
    PubMed     Abstract available


  90. LIU Y, Huang Q, Wei Z, Ma S, et al
    GSK-3 mediates nuclear translocation of p62/SQSTM1 in MPTP-induced mouse model of Parkinson's disease.
    Neurosci Lett. 2021 Aug 13:136177. doi: 10.1016/j.neulet.2021.136177.
    PubMed     Abstract available


  91. TU HY, Gu YQ, Li X, Pei SF, et al
    Expression of autophagy related genes in peripheral blood cells in Parkinson's disease.
    Neurosci Lett. 2021 Aug 6:136166. doi: 10.1016/j.neulet.2021.136166.
    PubMed     Abstract available


  92. ZHENG R, Qiao S, Chen Y, Jin C, et al
    Association analysis and polygenic risk score evaluation of 38 GWAS-identified Loci in a Chinese population with Parkinson's disease.
    Neurosci Lett. 2021;762:136150.
    PubMed     Abstract available


  93. TANG C, Zhao X, Wu W, Zhong W, et al
    An individualized prediction of time to cognitive impairment in Parkinson's disease: a combined multi-predictor study.
    Neurosci Lett. 2021 Aug 2:136149. doi: 10.1016/j.neulet.2021.136149.
    PubMed     Abstract available


    July 2021
  94. SALJUQI M, Ghaderyan P
    A novel method based on matching pursuit decomposition of gait signals for Parkinson's disease, Amyotrophic lateral sclerosis and Huntington's disease detection.
    Neurosci Lett. 2021 Jul 10:136107. doi: 10.1016/j.neulet.2021.136107.
    PubMed     Abstract available


    June 2021
  95. BAI X, Dong Q, Zhao L, Yao Y, et al
    microRNA-106b-containing extracellular vesicles affect autophagy of neurons by regulating CDKN2B in Parkinson's disease.
    Neurosci Lett. 2021 Jun 30:136094. doi: 10.1016/j.neulet.2021.136094.
    PubMed     Abstract available


  96. DA SILVA WAB, Ferreira Oliveira K, Caroline Vitorino L, Ferreira Romao L, et al
    Physical exercise increases the production of tyrosine hydroxylase and CDNF in the spinal cord of a Parkinson's disease mouse model.
    Neurosci Lett. 2021 Jun 25:136089. doi: 10.1016/j.neulet.2021.136089.
    PubMed     Abstract available


  97. SUN D, Wu X, Xia Y, Wu F, et al
    Differentiating Parkinson's Disease Motor Subtypes: A Radiomics Analysis Based on Deep Gray Nuclear Lesion and White Matter.
    Neurosci Lett. 2021 Jun 23:136083. doi: 10.1016/j.neulet.2021.136083.
    PubMed     Abstract available


  98. YIN K, Zhou C, Yin L, Zhu Y, et al
    Resting-state functional magnetic resonance imaging of the cerebellar vermis in patients with Parkinson's disease and visuospatial disorder.
    Neurosci Lett. 2021;760:136082.
    PubMed     Abstract available


  99. XU X, He X, Ma S, Li M, et al
    Nurr1 downregulation is caused by CREB inactivation in a Parkinson's disease mouse model.
    Neurosci Lett. 2021;759:136045.
    PubMed     Abstract available


  100. NIYOMRAT K, Cheaha D, Nukitram J, Kumarnsit E, et al
    Locomotor activity and resting local field potential oscillatory rhythms of 6-OHDA mouse model of Parkinson's disease in response to acute and repeated treatments with L-dopa.
    Neurosci Lett. 2021 Jun 4:136007. doi: 10.1016/j.neulet.2021.136007.
    PubMed     Abstract available


    May 2021
  101. LI N, Suo X, Zhang J, Lei D, et al
    Disrupted functional brain network topology in Parkinson's disease patients with freezing of gait.
    Neurosci Lett. 2021 May 20:135970. doi: 10.1016/j.neulet.2021.135970.
    PubMed     Abstract available


  102. TAKAHASHI K, Iwaoka K, Takahashi K, Suzuki Y, et al
    Cerebrospinal fluid levels of oxidative stress measured using diacron-reactive oxygen metabolites and biological antioxidant potential in patients with Parkinson's disease and progressive supranuclear palsy.
    Neurosci Lett. 2021 May 20:135975. doi: 10.1016/j.neulet.2021.135975.
    PubMed     Abstract available


  103. RONG Z, Shen F, Wang Y, Sun L, et al
    Phosphorylated alpha-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis.
    Neurosci Lett. 2021;756:135964.
    PubMed     Abstract available


    April 2021
  104. VENKATESAN D, Iyer M, S RW, G L, et al
    The association between multiple risk factors, clinical correlations and molecular insights in Parkinson's disease patients from Tamil Nadu population, India.
    Neurosci Lett. 2021;755:135903.
    PubMed     Abstract available


  105. SALAS-LEAL AC, Salas-Pacheco SM, Gavilan-Ceniceros JAP, Castellanos-Juarez FX, et al
    alpha-syn and SNP rs356219 as a potential biomarker in blood for Parkinson's disease in Mexican Mestizos.
    Neurosci Lett. 2021;754:135901.
    PubMed     Abstract available


  106. ZHANG L, He Y, Lei K, Fang Z, et al
    Gene expression profiling of early Parkinson's disease patient reveals redox homeostasis.
    Neurosci Lett. 2021;753:135893.
    PubMed     Abstract available


  107. BAI X, Liu X, Li X, Li W, et al
    Association between VPS13C rs2414739 polymorphism and Parkinson's disease risk: A meta-analysis.
    Neurosci Lett. 2021 Apr 7:135879. doi: 10.1016/j.neulet.2021.135879.
    PubMed     Abstract available


  108. RAJ K, Kaur P, Gupta GD, Singh S, et al
    Metals associated neurodegeneration in Parkinson's disease: Insight to physiological, pathological mechanisms and management.
    Neurosci Lett. 2021;753:135873.
    PubMed     Abstract available


  109. KAKOTY V, K C S, Dubey SK, Yang CH, et al
    The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy.
    Neurosci Lett. 2021;753:135865.
    PubMed     Abstract available


  110. WERNICK AI, Walton RL, Soto-Beasley AI, Koga S, et al
    Investigating ELOVL7 coding variants in multiple system atrophy.
    Neurosci Lett. 2021;749:135723.
    PubMed     Abstract available


    March 2021
  111. NAUSHAD SM, Hussain T, Alrokayan S, Kutala VK, et al
    Alpha synuclein (SNCA) rs7684318 variant contributes to Parkinson's disease risk by altering transcription factor binding related with Notch and Wnt signaling.
    Neurosci Lett. 2021 Mar 8:135802. doi: 10.1016/j.neulet.2021.135802.
    PubMed     Abstract available


    February 2021
  112. KAKOTY V, Sarathlal KC, Dubey SK, Yang CH, et al
    Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson disease.
    Neurosci Lett. 2021 Feb 23:135769. doi: 10.1016/j.neulet.2021.135769.
    PubMed     Abstract available


  113. SHARMA T, Kaur D, Grewal AK, Singh TG, et al
    Therapies modulating insulin resistance in Parkinson's disease: A cross talk.
    Neurosci Lett. 2021 Feb 18:135754. doi: 10.1016/j.neulet.2021.135754.
    PubMed     Abstract available


  114. SIOKAS V, Arseniou S, Aloizou AM, Tsouris Z, et al
    CD33 rs3865444 as a risk factor for Parkinson's disease.
    Neurosci Lett. 2021 Feb 11:135709. doi: 10.1016/j.neulet.2021.135709.
    PubMed     Abstract available


    January 2021
  115. GUO W, Jin W, Li N, Gao J, et al
    Brain activity alterations in patients with Parkinson's disease with cognitive impairment based on resting-state functional MRI.
    Neurosci Lett. 2021 Jan 27:135672. doi: 10.1016/j.neulet.2021.135672.
    PubMed     Abstract available


  116. LEE SH, Han YT, Cha DS
    Neuroprotective effect of damaurone D in a C. elegans model of Parkinson's Disease.
    Neurosci Lett. 2021 Jan 19:135623. doi: 10.1016/j.neulet.2021.135623.
    PubMed     Abstract available


  117. ZHANG L, Yang H
    Promotive effects of tetrahydroxystilbene glucoside on the differentiation of neural stem cells from the mesencephalon into dopaminergic neurons.
    Neurosci Lett. 2021;742:135520.
    PubMed     Abstract available


  118. DONG MX, Hu L, Wei YD, Chen GH, et al
    Metabolomics profiling reveals altered lipid metabolism and identifies a panel of lipid metabolites as biomarkers for Parkinson's disease related anxiety disorder.
    Neurosci Lett. 2021 Jan 10:135626. doi: 10.1016/j.neulet.2021.135626.
    PubMed     Abstract available


  119. TAGHIZADEH G, Joghataei MT, Goudarzi S, Bakhsheshi M, et al
    King's Parkinson's disease Pain Scale Cut-off Points for Detection of Pain Severity Levels: A Reliability and Validity Study.
    Neurosci Lett. 2021 Jan 8:135620. doi: 10.1016/j.neulet.2020.135620.
    PubMed     Abstract available


    December 2020
  120. YU LH, Peng GP, Yuan Y, Liu XY, et al
    Novel compound heterozygous of PARKIN causes early-onset Parkinson's disease.
    Neurosci Lett. 2020;744:135597.
    PubMed     Abstract available


    November 2020
  121. FLORES-SOTO ME, Corona-Angeles JA, Tejeda-Martinez AR, Flores-Guzman PA, et al
    beta-CARYOPHYLLENE EXERTS PROTECTIVE ANTIOXIDANT EFFECTS THROUGH THE ACTIVATION OF NQO1 IN THE MPTP MODEL OF PARKINSON'S DISEASE.
    Neurosci Lett. 2020 Nov 30:135534. doi: 10.1016/j.neulet.2020.135534.
    PubMed     Abstract available


  122. USENKO TS, Bezrukova AI, Bogdanova DA, Kopytova AE, et al
    Genetics variants and expression of the SCARB2 gene in the pathogenesis of Parkinson's disease in Russia.
    Neurosci Lett. 2020 Nov 20:135509. doi: 10.1016/j.neulet.2020.135509.
    PubMed     Abstract available


  123. WANG S, Zhang Y, Lei J, Guo S, et al
    Investigation of Sensorimotor Dysfunction in Parkinson Disease by Resting-state fMRI.
    Neurosci Lett. 2020 Nov 19:135512. doi: 10.1016/j.neulet.2020.135512.
    PubMed     Abstract available


  124. LI MG, Bian XB, Zhang J, Wang ZF, et al
    Aberrant Voxel-based Degree Centrality in Parkinson's Disease Patients with Mild Cognitive Impairment.
    Neurosci Lett. 2020 Nov 17:135507. doi: 10.1016/j.neulet.2020.135507.
    PubMed     Abstract available


  125. QI H, Shen D, Jiang C, Wang H, et al
    Ursodeoxycholic acid protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis in MPTP/MPP(+)-induced Parkinson's disease.
    Neurosci Lett. 2020 Nov 9:135493. doi: 10.1016/j.neulet.2020.135493.
    PubMed     Abstract available


  126. LIU Z, Ye Q, Wang F, Guo Y, et al
    Protective effect of thioredoxin reductase 1 in Parkinson's disease.
    Neurosci Lett. 2020 Nov 7:135457. doi: 10.1016/j.neulet.2020.135457.
    PubMed     Abstract available


  127. BALTUS THL, Morelli NR, de Farias CC, Trugilo KP, et al
    Association of -94 ATTG insertion/deletion NFkB1 and c.*126G>A NFkBIA genetic polymorphisms with oxidative and nitrosative stress biomarkers in Brazilian subjects with Parkinson's Disease.
    Neurosci Lett. 2020;740:135487.
    PubMed     Abstract available


  128. HUANG S, Zhao Z, Ma J, Hu S, et al
    Increased plasma orexin-A concentrations are associated with the Non-motor symptoms in Parkinson's disease patients.
    Neurosci Lett. 2020 Nov 5:135480. doi: 10.1016/j.neulet.2020.135480.
    PubMed     Abstract available


  129. YANG Q, Nanivadekar S, Taylor PA, Dou Z, et al
    Executive function network's white matter alterations relate to Parkinson's disease motor phenotype.
    Neurosci Lett. 2020 Nov 5:135486. doi: 10.1016/j.neulet.2020.135486.
    PubMed     Abstract available


    October 2020
  130. SAHAI S, Effendi ET, Mahoney EC, Tucker HR, et al
    Effects of subthalamic nucleus deep brain stimulation on neuronal spiking activity in the substantia nigra pars compacta in a rat model of Parkinson's disease.
    Neurosci Lett. 2020;739:135443.
    PubMed     Abstract available


  131. SONG MK, Lee JH, Kim J, Kim JH, et al
    Neuroprotective effect of NXP031 in the MPTP-induced Parkinson's disease model.
    Neurosci Lett. 2020 Oct 16:135425. doi: 10.1016/j.neulet.2020.135425.
    PubMed     Abstract available


  132. KESH S, Kannan RR, Sivaji K, Balakrishnan A, et al
    Hesperidin downregulates kinases lrrk2 and gsk3beta in a 6-OHDA induced Parkinson's disease model.
    Neurosci Lett. 2020 Oct 16:135426. doi: 10.1016/j.neulet.2020.135426.
    PubMed     Abstract available


    September 2020
  133. SUBRAMANIAN N, Ramanathan S, Venkatesan V, Koshy T, et al
    A Case-Control Association of RANTES (-28C >G) and CCR5-Delta32 Polymorphisms with Parkinson's Disease in Indians.
    Neurosci Lett. 2020 Sep 25:135404. doi: 10.1016/j.neulet.2020.135404.
    PubMed     Abstract available


    April 2020
  134. LENG B, Sun H, Zhao J, Liu Y, et al
    Plasma exosomal prion protein levels are correlated with cognitive decline in PD patients.
    Neurosci Lett. 2020;723:134866.
    PubMed     Abstract available


    February 2020
  135. FURLONG RM, O'Keeffe GW, O'Neill C, Sullivan AM, et al
    Alterations in alpha-synuclein and PINK1 expression reduce neurite length and induce mitochondrial fission and Golgi fragmentation in midbrain neurons.
    Neurosci Lett. 2020;720:134777.
    PubMed     Abstract available


    January 2020
  136. SANNA A, Follesa P, Puligheddu M, Cannas A, et al
    Cerebellar continuous theta burst stimulation reduces levodopa-induced dyskinesias and decreases serum BDNF levels.
    Neurosci Lett. 2020;716:134653.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.